C-POLAR ™ Technologies, Inc. is launched in the United States

Business consolidation of C-POLAR ™ Biotech Limited Hong Kong and Polarität LLC completed

C-POLARTM Technologies, Inc. launches itself as an international leader in bioprotection against viruses and microorganisms, setting the new standard in health and safety with revolutionary technology that has been shown to stop, inactivate and eradicate up to 99.9% of viruses and microorganisms.

LAS VEGAS, June 27, 2022 (GLOBE NEWSWIRE) – C-POLAR ™ Technologies Inc., a biotechnology protection company dedicated to setting the new health and safety standard through virus and microorganism protection, announced the successful business consolidation of C-POLAR ™ Biotech Limited Hong Kong and Polarität LLC to form the company. The consolidation brings together two companies focused on developing and commercializing cutting-edge technologies that better protect against harmful viruses, microorganisms and other pathogens with a world-class international team with unparalleled experience in business and technology.

Since most viruses and microorganisms, such as COVID-19, have a negatively charged protective layer, C-POLAR ™ technology uses a positive polymeric material to stop negatively charged pathogens upon contact. The virus or microorganism is then inactivated as the C-POLAR ™ material tears the envelope and / or destroys the protein membrane. Finally, the C-POLAR ™ material disintegrates the protein envelope and protein membranes, effectively destroying the virus or microorganism.

C-POLAR ™ technology has been validated through rigorous testing studies at multiple top academic institutions and real world applications to be sustainable, safe, low cost and effective in eliminating even the most dangerous pathogens. To date, technology case studies have been completed by Harvard Medical School, University of Minnesota, Finnish University of Tempere, Hong Kong Metropolitan University, Nelson Labs, Intertek, and the Academy of Sciences. Czech. The company has also launched real-world applications of its technology in collaboration with the International Commerce Center (ICC), China Minmetals Tower, Hong Kong Convention and Exhibition Center, Hong Kong Baptist Hospital, AsiaWorld Expo, Bank of America Tower and over 200 other buildings around the world. The inaugural application of C-POLAR ™ technology features commercial-grade air filtration and personal face masks. C-POLAR ™ plans to rapidly expand its application offering across a wide range of other industries such as medical devices, wound care and water filtration.

“As the past two years of living with the COVID-19 virus have shown, viruses, mutated bacteria and airborne pathogens have the ability to dramatically disrupt society and our individual lives. For our global community to return to normal, it is urgent to innovate and upgrade our existing infrastructure to better protect ourselves from harmful viruses and microorganisms, “said Steve Gorlin, President of C-POLAR ™ Technologies.” C-POLAR ™ represents an incredible breakthrough in biosecurity science and the important role of international cooperation in delivering world-changing results. We are extremely excited to bring this technology to various industries around the world to effectively reduce the chaos these microorganisms can cause in our lives daily “.

Recognizing the need for cost-effective, safe and sustainable solutions, C-POLAR ™ Technologies’ patented material is made from natural, plant-based, non-toxic and safe material. Unlike other bioprotection alternatives such as UV light technology, the C-POLAR ™ material is 100% safe for direct human contact, is free of metal ions and complies with the highest safety standards established by major international and North American regulatory bodies. The main ingredient of the C-POLAR ™ material has been approved as a food additive by the WHO, FDA and FAO. In addition, the UK’s National Health Service (NHS) has tested and adopted C-POLAR ™ spunlace as the raw material for their FFP3 respirators, which are specifically designed for NHS frontline healthcare professionals.

C-POLAR ™ Technologies Inc. will operate with an international team based in the United States and international offices in Canada, the Czech Republic and Hong Kong.

About C-POLAR ™ Technologies Inc.
C-POLAR ™ Technologies Inc. is dedicated to protecting against viruses and microorganisms. The company’s proprietary technology, C-POLARTM material is highly effective and efficient where numerous international studies have demonstrated its ability to arrest, inactivate and eradicate up to 99.9% of viruses and microorganisms. C-POLAR ™ material is 100% safe, non-toxic and made from natural plant-based materials that allow it to be highly versatile and applicable to endless industries and applications.

Contact:
Matteo Cossel
Strategic Communications KCSA
[email protected]
347-487-7704

Leave a Comment

Your email address will not be published.